Alligator Bioscience Ab · OMXSTO:ATORX

Alligator Bioscience Ab — Biotech Showcase 2017

21 slides from Alligator Bioscience Ab's conference presentation, Jan 10, 2017

1. Slide 1: Company presentation

   Company presentation Biotech Showcase, San Fransisco, 10 January 2017 Per Norlén, CEO

2. Slide 2: Disclaimer

   Disclaimer This presentation regarding Alligator Bioscience AB (“Alligator”) and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, by any medium or for any purpose. This presentation doe

3. Slide 3: Alligator Bioscience in brief

   Alligator Bioscience in brief COMPANY HIGHLIGHTS HISTORY OF ASSET GROWTH Development of tumor-directed immuno-oncology antibodies to out-license after POC ADC-1013 entering clinical phase I 2015 and major out-licensing deal Fast growing market for immuno-oncology drugs with estimated US$ +30 billion

4. Slide 4: Rapid uptake and development within the field of immuno-oncology

   Rapid uptake and development within the field of immuno-oncology Sales of existing immuno-oncology treatments Market potential for immuno-oncology US$ Million Annual global cancer mortality (2012) ~34,000 Of which melanoma <80,000 deaths Lung 1 589 800 Liver Stomach 2 623 336 Colorectum Breast 5 126

5. Slide 5: Introduction to tumor-directed immuno-oncology

   Introduction to tumor-directed immuno-oncology Metastases Immune activation Tumor S Y S T E M I C I M M U N O - A C T I V AT I O N T U M O R - D I R E C T E D I M M U N O - A C T I V AT I O N Systemic administration of immunotherapeutic drugs results in Selective activation of tumor-specific immune

6. Slide 6: Fully integrated technology platforms

   Fully integrated technology platforms ALLIGATOR-GOLD® FIND® ALLIGATOR-GOLD® is a fully human The FIND® technology is used to optimize single-chain library with large diversity antibodies and other proteins characteristics D I V E R S I T Y > 1 0 10 OPTIMIZATION IMPROVED PRODUCT CANDIDATE  Increased

7. Slide 7: Extensive collaboration with distinguished immuno-oncologists

   Extensive collaboration with distinguished immuno-oncologists Partners and major deliverables The Royal Stanford Navarra Lund Uppsala University of EU/TIMCC Institute of University University University University Manchester Technology  Pre-clinical In-  In-vitro and in-  DC and T-cell  In-vivo

8. Slide 8: Well-positioned drug development pipeline

   Well-positioned drug development pipeline Pipeline of immuno-stimulating mono- and bi-specific antibodies targeting TNFR superfamily RESEARCH PRE-CLINICAL DEVELOPMENT PHASE I PHASE II ADC-1013* (CD40) ATOR-1015 (OX40/CTLA-4) ATOR-1016 (TNFR-SF/TAA) (TNFR-SF) (TNFR-SF/ND) TNFR-SF: Tumor Necrosis Fact

9. Slide 9: ADC-1013: CD40 is a key immuno-oncology target

   ADC-1013: CD40 is a key immuno-oncology target ADC-1013 Mode of Action Immuno-modulating receptors ANTIGEN-PRESENTING CELL T CELL ANTIGEN-PRESENTING CELL T CELL PDL1 or PDL2 ? + ADC-1013 PDL1 or PDL2 PD1 – CD40 CD80 or CD86 CD28 + CD80 or CD86 CTLA4 – B7RP1 ICOS + B7-H3 ? – B7-H4 ? – T cell Dendriti

10. Slide 10: ADC-1013: One of four CD40 mAbs in clinical phase

    ADC-1013: One of four CD40 mAbs in clinical phase Selection of antibody based immuno-oncology drugs in clinical development Comments Company Drug Indication Phase Target  Approx. 70 immuno-oncology drugs are currently in AstraZeneca (MedImmune) durvalumab NSCLC, H&N, bladder III PD-L1 clinical deve

11. Slide 11: ADC-1013: Anti-tumor effect in lymphoma model

    ADC-1013: Anti-tumor effect in lymphoma model Results from single tumor model in A20 lymphoma 700 100 90 600 80 500 70 Tumor volume (mm³) Survival (%) 60 400 50 300 40 200 30 20 100 10 0 0 0 5 10 15 20 25 30 0 20 40 60 80 Time (days) Time (days) Ctrl IgG ADC-1013 Ctrl IgG ADC-1013 ADC-1013 induces s

12. Slide 12: ADC-1013: Long term immunity in bladder model

    ADC-1013: Long term immunity in bladder model Results from rechallenge in a twin-tumor model 140 120 100 Tumor volume (mm³) 80 60 40 20 0 0 2 4 6 8 10 12 14 Time (days) Re-challenge with a different tumor Re-challenge with the same tumor Type LLC1 lung cancer Type MB49 bladder cancer Mice previously

13. Slide 13: ADC-1013: Partnership with Janssen validating Alligator's model

    ADC-1013: Partnership with Janssen validating Alligator’s model Partnership details for ADC-1013 Description of ongoing Phase I trial Description of agreement Royalty / Milestone potential  40 patients with advanced solid  Exclusive world-wide  Up-front payment plus tumors license to ADC-1013 add

14. Slide 14: ATOR-1015: Biological rationale for dual binding OX40 and CTLA-4

    ATOR-1015: Biological rationale for dual binding OX40 and CTLA-4 Design and optimization of the CTLA-4 binding part Anti-OX40 ATOR-1015 Anti-CTLA-4 5 mutations were introduced  Affinity increased 100-fold Mode of Action T-cell T-cell  ACTIVATION OF ATOR-1015 DEPLETION OF EFFECTOR T-CELLS REGULATOR

15. Slide 15: ATOR-1015: Combining OX40 with CTLA-4 (1/3)

    ATOR-1015: Combining OX40 with CTLA-4 (1/3) OX40 and CTLA-4 surrogate antibodies (30μg of each) 2 500 2 000 Tumor volume (mm³) 1 500 1 000 500 0 0 5 10 15 20 25 30 Time (days) Ctr IgG (right tumor) Ctr IgG (left tumor) OX40 and CTLA4 (right tumor) OX40 and CTLA4 (left tumor) Source: Hebb and Kohrt,

16. Slide 16: ATOR-1015: Combining OX40 with CTLA-4 (2/3)

    ATOR-1015: Combining OX40 with CTLA-4 (2/3) CTLA-4 mediated clustering of OX40 Synergistic T-eff activation ATOR-1015 CTLA-4 mediated No clustering clustering  No/low immune Combination of monospecific αOX40 and αCTLA-4  Strong immune activation 6 000 activation 5 000 T-eff T-eff 4 000 IL-2 (pg/ml

17. Slide 17: ATOR-1015: Combining OX40 with CTLA-4 (3/3)

    ATOR-1015: Combining OX40 with CTLA-4 (3/3) ATOR-1015 induces ADCC on CTLA-4/OX40 expressing cells Synergistic T-cell depletion 140 120 ADCC (fold induction) T-cell 100 80 MΦ 60 40 20 0 0,001 0,01 0,1 1 10 100 1000  When ATOR-1015 binds to cells that express high levels Conc. log (nM) of OX40 and C

18. Slide 18: ATOR-1016: Localizing tumor-directed immunotherapy

    ATOR-1016: Localizing tumor-directed immunotherapy Mode of Action Major benefits of localizing immune-activators NOTE: ILLUSTRATIVE ANTIBODY STRUCTURE – FINAL STRUCTURE NOT DISCLOSED Immune-activators inactive until reaching tumor T-cell DC ACTIVATION Systemic administration T-cell TUMOR ACTIVATION

19. Slide 19: Solid intellectual property portfolio

    Solid intellectual property portfolio  More than 50 approved and/or pending patents  Seven product patent families, including ADC-1013  Solid IP position for ADC-1013 with patent coverage at least until 2032  Four technology patent families, including FIND® and ALLIGATOR-GOLD®  Covering all maj

20. Slide 20: Strategy to maximize shareholder value

    Strategy to maximize shareholder value 1. Advance and broaden pipeline of agonistic tumor- PHASE II directed immuno-oncology antibodies ADC-1013 PHASE I 2. Extend in-house product development to later- stage clinical phase prior to partnering PRE-CLINICAL ATOR-1015 DEVELOPMENT 3. Development of next

21. Slide 21: Thank You

    SS Se Thank You

Alligator Bioscience — Biotech Showcase 2017 on 6ix